Medical inquiries

Phone: +41 (0)41 767 7255

Mon - Fri 09.00 - 17.00

Email: medinfo.switzerland@bms.com

Websites for your patients

Useful disease information for your patients in a patient-friendly language:

BMS Events

Interested in attending a round table event or learning about BMS' presence at congresses? Check out our events section for information on past and upcoming events in various therapy areas.

 

 

This page provides you with brief summaries of our pivotal clinical trial data and comprehensive information on our approved indications and reimbursement policies for our innovative cancer treatments. Our portfolio of oncology medicines includes innovative therapies that target key biological pathways and expand our understanding of immune cell therapy. Explore our oncology medicines and learn how we are contributing to the advancement of cancer treatment.

 

 

 

 

 

 

Recent approvals

 

Icons
Melanoma

October 2023 – Nivolumab as monotherapy is indicated for the adjuvant treatment of adults with completely resected Stage IIB or IIC melanoma.

More information

Icons
Melanoma

November 2023 – Q4W 480 mg dosing with Nivolumab is approved in all melanoma indications.

Q4W dosing is approved for all Nivolumab monotherapy in melanoma as well as monotherapy maintenance after Nivolumab + Ipilimumab combination treatment

More information

 

 

Icons
Thoracic cancer

July 2023 – Nivolumab in combination with platinum-based chemotherapy for the neoadjuvant treatment of resectable (tumor size ≥ 4cm or positive lymph node involvement) non-small cell lung cancer (NSCLC) with PD-L1 tumor expression ≥1% in adults

More information

Icons
Melanoma

December 2022 – Nivolumab/Relatlimab for the first-line treatment of adults with unresectable or metastatic melanoma with PD-L1 expression < 1%.

More information

 

 

 

 

Cancer type

 

 

 

10/2023 7356-CH-2300049